Latest Australian Securities News

Gateway Mining Limited has requested a voluntary suspension of its ASX-listed securities pending an important announcement on exploration results from its Yandal Gold Project, expected by 26 August 2025.

Piedmont Lithium Inc. has halted trading on the ASX as it finalises a merger with Sayona Mining Limited, marking a significant restructuring in the lithium mining sector.

Magnetite Mines Limited faces immediate suspension of its MGTOF securities from ASX quotation due to non-compliance with listing rules, raising questions about regulatory hurdles ahead.

Vonex Limited shareholders will soon decide on a court-approved scheme of arrangement under which Maxo Telecommunications will acquire the remaining 30.6% of Vonex shares it does not already own, offering an 80% premium to the pre-announcement share price.

Underwood Capital Limited has reported a return to profitability for the year ended 30 June 2025, driven by gains in its listed securities portfolio and a strategic share buyback that enhanced net tangible asset backing per share.

Xamble Group Limited has clarified that its recent share price surge is linked to a newly announced renounceable rights issue, dismissing speculation of undisclosed information.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

Cannindah Resources Limited has had its trading suspension lifted immediately following the release of a capital raising announcement, signaling renewed market activity.

The ASX has suspended the securities of 36 companies for failing to pay their annual listing fees by the August 21 deadline, with a looming delisting threat if fees remain unpaid by August 28.

Piedmont Lithium has released an updated timetable for its merger with Sayona Mining, marking key dates for stockholder approval, trading suspensions, and the final merger close by late August 2025.

Omnia Metals Group Limited has issued a prospectus to list up to 10,000 options, aiming to remove trading restrictions and facilitate secondary market activity. This move follows recent capital raisings and shareholder approvals, positioning the company for enhanced liquidity.

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.